Nuzenio

Fda Approves Pluvicto

Fda Approves Pluvicto news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 21 latest news signals 20 publisher sources 100/100 entity strength

Latest news

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMT FDA Expands Approval of Pluvicto® for Metastatic Prostate Cancer: Targets a Protein Called PSMA - Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center · Thu, 06 Aug 2026 04:00:00 GMT FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 10:28:25 GMT FDA Approves Pluvicto for Earlier Use in Prostate Cancer - SurvivorNetSurvivorNet · Tue, 04 Aug 2026 17:34:02 GMT FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Mon, 03 Aug 2026 17:37:08 GMT FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - BenzingaBenzinga · Mon, 03 Aug 2026 16:56:48 GMT FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients - Endpoints NewsEndpoints News · Mon, 03 Aug 2026 15:26:00 GMT Novartis Pluvicto FDA approval doubles mHSPC patient pool - scanx.tradescanx.trade · Mon, 03 Aug 2026 15:07:31 GMT

Timeline

Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis

Thu, 06 Aug 2026 04:00:00 GMTFDA Expands Approval of Pluvicto® for Metastatic Prostate Cancer: Targets a Protein Called PSMA - Memorial Sloan Kettering Cancer Center

Wed, 05 Aug 2026 10:28:25 GMTFDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - Oncodaily

Tue, 04 Aug 2026 17:34:02 GMTFDA Approves Pluvicto for Earlier Use in Prostate Cancer - SurvivorNet

Mon, 03 Aug 2026 17:37:08 GMTFDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer - The American Journal of Managed Care

Mon, 03 Aug 2026 16:56:48 GMTFDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Benzinga

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

Pluvicto21 live mentions PSMA16 live mentions FDA11 live mentions S Prostate Cancer6 live mentions Novartis5 live mentions Metastatic Prostate Cancer4 live mentions Positive4 live mentions FDA Expands Approval3 live mentions Earlier3 live mentions Oncology Nursing News3 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Fda Approves Pluvicto.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

20 distinct publisher/source names are currently connected to this entity page.